UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000053365
Receipt number R000060908
Scientific Title Exploratory study of the effect of oligosaccharide intake on gut microbiota, blood marker, and physical condition
Date of disclosure of the study information 2024/01/19
Last modified on 2024/01/16 13:18:51

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Exploratory study of the effect of oligosaccharide intake on gut microbiota, blood marker, and physical condition

Acronym

Exploratory study of the effect of oligosaccharide intake on gut microbiota, blood marker, and physical condition

Scientific Title

Exploratory study of the effect of oligosaccharide intake on gut microbiota, blood marker, and physical condition

Scientific Title:Acronym

Exploratory study of the effect of oligosaccharide intake on gut microbiota, blood marker, and physical condition

Region

Japan


Condition

Condition

Healthy adult

Classification by specialty

Not applicable

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To examine the effect of four weeks of oligosaccharide intake on gut microbiota, blood marker, and physical condition

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

gut microbiota

Key secondary outcomes

fecal organic acid concentration, fecal bile acid concentration, blood marker, physical conditions (height, body weight, BMI, muscle mass, body fat mass, body fat percentage, blood pressure), and incidence of adverse events


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Self control

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

No need to know


Intervention

No. of arms

1

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Oral ingestion of oligosaccharide for four weeks

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1.Those who provided specimens in which oligosaccharide increased the number of useful bacteria in vitro
2.Those who belongs to R&D division on the date of consent
3.Those who have received sufficient explanation about the purpose and content of this study, have the consent ability and good understandings, and have agreed voluntarily to participate in the study

Key exclusion criteria

1.Those who have participated in other intervention studies in the month prior to screening or who plan to participate in other intervention studies during the period from screening to the end of the intake period
2.Those who have a history of gastric or lower gastrointestinal tract surgery excluding hemorrhoids
3.Those who have a barium stomach X-ray, small or large intestine endoscopy, or bowel cleansing at a clinic or at home in the month prior to screening or who plan to have these procedures during this study
4.Those who have taken, ingested, or used drugs that may affect the study at least once a week in the month prior to screening, or who plan to take, ingest, or use these drugs at least once during the study
5.Those who plan to travel abroad, travel for more than one week, or go on a business trip during the period from one week prior to the intake period to the end of the intake period
6.Those with lactose intolerance
7.Those with milk allergy
8.Females who are pregnant and/or lactating
9.Those judged as unsuitable for the study by the principal investigator or research physician for other reasons

Target sample size

60


Research contact person

Name of lead principal investigator

1st name Seiya
Middle name
Last name Makino

Organization

Meiji Co., Ltd.

Division name

R&D Division

Zip code

192-0919

Address

1-29-1 Nanakuni, Hachiouji, Tokyo

TEL

042-632-5838

Email

seiya.makino@meiji.com


Public contact

Name of contact person

1st name Seiya
Middle name
Last name Makino

Organization

Meiji Co., Ltd.

Division name

R&D Division

Zip code

192-0919

Address

1-29-1 Nanakuni, Hachiouji, Tokyo

TEL

042-632-5838

Homepage URL


Email

seiya.makino@meiji.com


Sponsor or person

Institute

Meiji Co., Ltd.

Institute

Department

Personal name



Funding Source

Organization

Meiji Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Meiji Institutional Review Board

Address

1-29-1 Nanakuni, Hachiouji, Tokyo

Tel

042-632-5900

Email

MEIJI.IRB@meiji.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2024 Year 01 Month 19 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2023 Year 12 Month 14 Day

Date of IRB


Anticipated trial start date

2024 Year 01 Month 26 Day

Last follow-up date

2024 Year 06 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2024 Year 01 Month 16 Day

Last modified on

2024 Year 01 Month 16 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000060908


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name